New ATC code Substance name

A02BD16 omeprazole, amoxicillin and rifabutin

A16AB21 atidarsagene autotemcel
A16AB22 avalglucosidase alfa
C03DA05 finerenone
C10BA12 pravastatin, ezetimibe and fenofibrate
D11AX27 oxymetazoline
H01AC08 somatrogon
H01CC04 linzagolix
J05AB17 brincidofovir
J05AP12 coblopasvir
J05AX31 lenacapavir
J06BD03 tixagevimab and cilgavimab
J07BX04 dengue virus vaccines
L01AA10 melphalan flufenamide
L01EJ03 pacritinib
L01EN03 infigratinib
L01EN04 futibatinib
L01FD05 trastuzumab duocarmazine
L01FF09 tislelizumab
L01FF10 retifanlimab
L01FX16 oportuzumab monatox
L01FX17 sacituzumab govitecan
L01FX18 amivantamab
L01XX74 belzutifan
L02BX04 relugolix
L03AB16 peginterferon alfacon-2
L04AA54 pegcetacoplan
L04AA55 sutimlimab
L04AA56 deucravacitinib
L04AC22 spesolimab
M02AA31 loxoprofen
M09AX13 casimersen
N02AJ16 tramadol and celecoxib
N02AX07 oliceridine
N02CD07 atogepant
N03AX27 ganaxolone
N05BA25 mexazolam
N06AX28 levomilnacipran
N07XX17 arimoclomol
R03CC15 formoterol
R05DB29 gefapixant
S01GX13 bilastine
V03AX04 difelikefalin
V10XA03 iodine (131I) omburtamab
A02BC09 tegoprazan
A05AX04 maralixibat chloride
A05AX05 odevixibat
A08AA12 setmelanotide
A10BD27 metformin, linagliptin and empagliflozin
A10BX15 imeglimin
A16AB20 pegunigalsidase alfa
A16AX19 fosdenopterin
A16AX20 lonafarnib
B03XA07 daprodustat
B03XA08 vadadustat
B06AC06 berotralstat
B06AX03 voxelotor
C08CA17 levamlodipine
C10AX17 evinacumab
C10AX18 volanesorsen
C10BA11 pravastatin and ezetimibe
D03AX15 trafermin
D10AX06 clascoterone
D11AH08 abrocitinib
J01RA14 norfloxacin and metronidazole
J01RA15 cefixime and ornidazole
J02AC06 oteseconazole
J05AB16 remdesivir
J07AG54 haemophilus influenza B, combinations with meningococcus C,Y, conjugated
J07BX03 covid-19 vaccines
L01EA06 asciminib
L01EX22 selpercatinib
L01EX23 pralsetinib
L01XC42 prolgolimab
L01XK06 pamiparib
L01XX72 tazemetostat
L01XX73 sotorasib
L04AA48 belumosudil
L04AA49 peficitinib
L04AA50 ponesimod
L04AA51 anifrolumab
L04AA52 ofatumumab
L04AA53 teprotumumab
L04AC20 netakimab
L04AC21 bimekizumab
L04AX09 diroximel fumarate
M05BX07 vosoritide
M09AX12 viltolarsen
N02AX51 tilidine and naloxone
N02BG12 tanezumab
N02CC08 lasmiditan
N02CD04 ubrogepant
N02CD05 eptinezumab
N02CD06 rimegepant
N05AD10 lumateperone
N05CM21 lemborexant
N06DX03 aducanumab
N07XX16 deutetrabenazine
P01AA30 tilbroquinol and tiliquinol
P01AB52 metronidazole and diloxanide
P01BB52 chloroquine and proguanil
P01BF07 artemisinin and piperaquine
P01BF08 artemisinin and naphthoquine
P01BF09 artesunate, sulfadoxine and pyrimethamine
P03AX07 abametapir
R03DX11 tezepelumab
S01EX07 ripasudil
S01GX12 cetirizine
S01LA08 bevacizumab
V03AF12 trilaciclib
V03AG05 sodium phosphate
V09GX05 ammonia (13N)
V09IX14 gallium (68Ga) PSMA-11
R06AA11 dimenhydrinate
Deadline for objections Implementation in the
ATC/DDD index (Year)
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Comment
1: Splitting of ATC code. Products containing dimenhydrinate (rINN)/diphenhydramine teoclate are moved to the new code. Product c
are moved to the new code. Product containing diphenhydramine chloride will remain in R06AA02.
ATC code New ATC level name

J06BD Antiviral monoclonal antibodies

L01EN Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors
L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
L01FA CD20 (Clusters of Differentiation 20) inhibitors
L01FB CD22 (Clusters of Differentiation 22) inhibitors
L01FC CD38 (Clusters of Differentiation 38) inhibitors
L01FD HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors
L01FE EGFR (Epidermal Growth Factor Receptor) inhibitors
L01FF PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors
L01FG VEGF/VEGFR (Vascular Endothelial Growth Factor) inhibitors
L01FX Other monoclonal antibodies
Deadline for objections Implementation in the
ATC/DDD index (Year)
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
Previous ATC code ATC level name New ATC code

J06BB16 palivizumab J06BD01

J06BB17 motavizumab J06BD02
J06BB18 raxibacumab J06BC02
J06BB21 bezlotoxumab J06BC03
J06BB22 obiltoxaximab J06BC04
L01EX16 erdafitinib L01EN01
L01EX20 pemigatinib L01EN02
L01XC Monoclonal antibodies deleted
L01XC01 edrecolomab L01FX01
L01XC02 rituximab L01FA01
L01XC03 trastuzumab L01FD01
L01XC05 gemtuzumab ozogamicin L01FX02
L01XC06 cetuximab L01FE01
L01XC07 bevacizumab L01FG01
L01XC08 panitumumab L01FE02
L01XC09 catumaxomab L01FX03
L01XC10 ofatumumab L01FA02
L01XC11 ipilimumab L01FX04
L01XC12 brentuximab vedotin L01FX05
L01XC13 pertuzumab L01FD02
L01XC14 trastuzumab emtansine L01FD03
L01XC15 obinutuzumab L01FA03
L01XC16 dinutuximab beta L01FX06
L01XC17 nivolumab L01FF01
L01XC18 pembrolizumab L01FF02
L01XC19 blinatumomab L01FX07
L01XC21 ramucirumab L01FG02
L01XC22 necitumumab L01FE03
L01XC23 elotuzumab L01FX08
L01XC24 daratumumab L01FC01
L01XC25 mogamulizumab L01FX09
L01XC26 inotuzumab ozogamicin L01FB01
L01XC27 olaratumab L01FX10
L01XC28 durvalumab L01FF03
L01XC29 bermekimab L01FX11
L01XC31 avelumab L01FF04
L01XC32 atezolizumab L01FF05
L01XC33 cemiplimab L01FF06
L01XC34 moxetumomab pasudotox L01FB02
L01XC35 tafasitamab L01FX12
L01XC36 enfortumab vedotin L01FX13
L01XC37 polatuzumab vedotin L01FX14
L01XC38 isatuximab L01FC02
L01XC39 belantamab mafodotin L01FX15
L01XC40 dostarlimab L01FF07
L01XC41 trastuzumab deruxtecan L01FD04
L01XC42 prolgolimab L01FF08
Deadline for objection to Implementation in the
temporary ATC code ATC/DDD index (Year)

9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
ATC code Previous ATC level name New ATC level name
J06BC Other immunoglobulins Antibacterial monoclonal antibodies
R05CA05 altheae root altheae radix
J02AC Triazole derivatives Triazole and tetrazole derivatives
P01AB51 metronidazole, combinations metronidazole and furazolidone
P01BB51 proguanil, combinations proguanil and atovaquone
Deadline for objection to temporary Implementation in the ATC/DDD
ATC level name index (Year)
9/1/2021 2022
9/1/2021 2022
Final 2022
Final 2022
Final 2022
ATC code ATC level name New DDD Unit Adm.route Note
A03FA07 itopride 0.15 g O
B02BX08 avatrombopag 20 mg O
B06AX01 crizanlizumab 12.5 mg P
H02CA03 ketoconazole 0.6 g O
J05AG05 rilpivirine 15 mg P
J05AJ04 cabotegravir 10 mg P
J05AJ04 cabotegravir 30 mg O
J05AX29 fostemsavir 1.2 g O
L04AA41 imlifidase 17.5 mg P course dose
L04AA43 ravulizumab 58.9 mg P
L04AA44 upadacitinib 15 mg O
N05CF04 eszopiclone 2 mg O
N06AX28 levomilnacipran 40 mg O
R03CC15 formoterol 0.16 mg O
A10BJ06 semaglutide 10.5 mg O
A16AB15 velmanase alfa 10 mg P
B03XA06 luspatercept 3.33 mg P
C08EX02 perhexiline 0.2 g O
J01MA15 gemifloxacin 0.2 g P
J05AB16 remdesivir 0.1 g P
J05AH01 zanamivir 1.2 g P
L02BB06 darolutamide 1.2 g O
L04AA38 ozanimod 0.92 mg O
N02BG11 mirogabalin 25 mg O
N03AX24 cannabidiol 0.7 g O
N05AL05 amisulpride 7.5 mg P
N06AX27 esketamine 8 mg N
V03AG05 sodium phosphate 8g O
L01EA01 imatinib 0.4 g O
L01EA02 dasatinib 0.1 g O
L01EA03 nilotinib 0.6 g O
L01EA04 bosutinib 0.4 g O
L01EA05 ponatinib 45 mg O
L01EB01 gefitinib 0.25 g O
L01EB02 erlotinib 0.15 g O
L01EB03 afatinib 40 mg O
L01EB04 osimertinib 80 mg O
L01EB07 dacomitinib 45 mg O
L01EC01 vemurafenib 1.92 g O
L01EC02 dabrafenib 0.3 g O
L01EC03 encorafenib 0.45 g O
L01ED01 crizotinib 0.5 g O
L01ED02 ceritinib 0.45 g O
L01ED03 alectinib 1.2 g O
L01ED04 brigatinib 0.18 g O
L01ED05 lorlatinib 0.1 g O
L01EE01 trametinib 2 mg O
L01EE02 cobimetinib 45 mg O
L01EE03 binimetinib 90 mg O
L01EF01 palbociclib 94 mg O
L01EF02 ribociclib 0.45 g O
L01EF03 abemaciclib 0.3 g O
L01EG01 temsirolimus 3.57 mg P
L01EG02 everolimus 10 mg O
L01EH01 lapatinib 1.25 g O
L01EH02 neratinib 0.24 g O
L01EH03 tucatinib 0.6 g O
L01EJ01 ruxolitinib 30 mg O
L01EJ02 fedratinib 0.4 g O
L01EK01 axitinib 10 mg O
L01EK03 tivozanib 1 mg O
L01EL01 ibrutinib 0.42 g O
L01EL02 acalabrutinib 0.2 g O
L01EL03 zanubrutinib 0.32 g O
L01EM01 idelalisib 0.3 g O
L01EM02 copanlisib 6.43 mg O
L01EM03 alpelisib 0.3 g O
L01EM04 duvelisib 50 mg O
L01EX01 sunitinib 33 mg O
L01EX02 sorafenib 0.8 g O
L01EX03 pazopanib 0.8 g O
L01EX04 vandetanib 0.3 g O
L01EX05 regorafenib 0.12 g O
L01EX07 cabozantinib 60 mg O
L01EX08 lenvatinib 18 mg O
L01EX09 nintedanib 0.38 g O
L01EX10 midostaurin 0.1 g O
L01EX12 larotrectinib 0.2 g O
L01EX13 gilteritinib 0.12 g O
L01EX14 entrectinib 0.6 g O
L01EX15 pexidartinib 0.8 g O
L01EX16 erdafitinib 9 mg O
L01EX17 capmatinib 0.8 g O
L01EX18 avapritinib 0.3 g O
L01EX19 ripretinib 0.15 g O
L01EX20 pemigatinib 9 mg O
L01EX22 selpercatinib 0.32 g O
L01EX23 pralsetinib 0.4 g O
Deadline for objection to Implementation in the
temporary DDD ATC/DDD index (Year)
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
9/1/2021 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
Final 2022
ATC code ATC level name Previous DDD Unit Adm.route New DDD
No DDD alterations decided
Unit Adm.route Note Deadline for objection to tempor Implementation in the ATC/DDD index (Year
in the ATC/DDD index (Year)